Molecular Mechanism of Nelumbinis Plumula Alkaloids in Prevention and Treatment of Non-Small Cell Lung Cancer: an Analysis Based on Network Pharmacology and Cell Experiment
Data Mining|更新时间:2021-06-25
|
Molecular Mechanism of Nelumbinis Plumula Alkaloids in Prevention and Treatment of Non-Small Cell Lung Cancer: an Analysis Based on Network Pharmacology and Cell Experiment
Chinese Journal of Experimental Traditional Medical FormulaeVol. 27, Issue 13, Pages: 164-171(2021)
CHENG Yan,LONG Hui-zhi,LUO Hong-yu,et al.Molecular Mechanism of Nelumbinis Plumula Alkaloids in Prevention and Treatment of Non-Small Cell Lung Cancer: an Analysis Based on Network Pharmacology and Cell Experiment[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(13):164-171.
CHENG Yan,LONG Hui-zhi,LUO Hong-yu,et al.Molecular Mechanism of Nelumbinis Plumula Alkaloids in Prevention and Treatment of Non-Small Cell Lung Cancer: an Analysis Based on Network Pharmacology and Cell Experiment[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(13):164-171. DOI: 10.13422/j.cnki.syfjx.20210912.
Molecular Mechanism of Nelumbinis Plumula Alkaloids in Prevention and Treatment of Non-Small Cell Lung Cancer: an Analysis Based on Network Pharmacology and Cell Experiment
To explore the potential molecular mechanism of Nelumbinis Plumula alkaloids (NAPs) in the prevention and treatment of non-small cell lung cancer (NSCLC) based on network pharmacology and cell experiment.
Method
2
The main active components of NAPs were obtained by searching Traditional Chinese Medicine System Pharmacology Database and Analysis Platform (TCMSP) and Bioinformatics Analysis Tool for Molecular Mechanism of Traditional Chinese Medicine (BATMAN-TCM), and their main targets were predicted and analyzed by employing Swiss Target Prediction. The main target genes of NSCLC were retrieved from GeneCards, Online Mendelian Inheritance in Man (OMIM) and DrugBank databases. The resulting common targets were imported into STRING platform for constructing the protein-protein interaction (PPI) network, followed by gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis based on Database for Annotation, Visualization, and Integrated Discovery (DAVID). The NAPs-common target -pathway network was constructed by Cytoscape 3.7.1. After NSCLC cell line A549 was treated with isoliensinine, the cell morphology was observed under an inverted fluorescence microscope. The effect of isoliensinine on A549 vitality was detected by cell counting kit-8 (CCK-8) assay and the target protein changes were verified by Western blot.
Result
2
The main active components for NAPs against NSCLC were lysicamine, liensinine, and isoliensinine. The phosphatidylinositol-3-kinase-protein kinase B (PI3K-AKT), RAS-related protein 1 (Rap1), epidermal growth factor family of receptor tyrosine kinases (ErbBs), and hypoxia inducible factor-1 (HIF-1) pathways were mainly involved for binding adenosine triphosphate (ATP) and regulating protein kinase activity. The main targets included protein kinase B-1 (AKT1), alpha catalytic subunit of phosphoinositol-3-kinase (PIK3CA), cyclin-dependent kinase 2 (CDK2), mitogen-activated protein kinase-1 (MAPK1), epidermal growth factor receptor (EGFR), adenosine triphosphate-binding cassette B1 (ABCB1), mammalian target of rapamycin (mTOR), tyrosine kinase (Src), Janus kinase 1 (JAK1), and G1-phase-specific gene cyclin-D
1
(CCND1). The
in vitro
cell experiment also revealed that isoliensinine down-regulated the expression of phosphorylated AKT (p-AKT) and phosphorylated mTOR (p-mTOR) in a concentration- and time-dependent manner and inhibited the growth of A549 cells.
Conclusion
2
NAPs exert the preventive and therapeutic effects against NSCLC through multiple components, multiple targets, and multiple pathways, especially the PI3K-AKT pathway.
BRAY F , FERLAY J , SOERJOMATARAM I , et al . Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin , 2018 , 68 ( 6 ): 394 - 424 .
CHEN S X , LI J , WU J , et al . Plumula nelumbinis:a review of tradition-al uses,phytochemistry,pharmacology,pharmacokinetics and safety [J]. J Ethnopharmacol , 2021 , 266 : 113429 .
PAUDEL K R , PANTH N . Phytochemical profile and biological activity of Nelumbo nucifera [J]. Evid Based Complement Alternat Med , 2015 , 2015 : 789124 .
LIN Z T , YANG R N , GUAN A , et al . Ultra-performance LC separation and quadrupole time-of-flight MS identification of major alkaloids in Plumula nelumbinis [J]. Phytochem Anal , 2014 , 25 ( 6 ): 485 - 494 .
VELLA D , MARINI S , VITALI F , et al . MTGO:PPI network analysis via topological and functional module identification [J]. Sci Rep , 2018 , 8 ( 1 ): 929 - 940 .
ZHAO X , SHEN J , CHANG K J , et al . Comparative analysis of antioxidant activity and functional components of the ethanol extract of lotus ( Nelumbo nucifera ) from various growing regions [J]. J Agric Food Chem , 2014 , 62 ( 26 ): 6227 - 6235 .
XIAO J H , ZHANG J H , CHEN H L , et al . Inhibitory effects of isoliensinine on bleomycin-induced pulmonary fibrosis in mice [J]. Planta Med , 2005 , 71 ( 3 ): 225 - 230 .
WANG gang , WANG ping , YAN Xiaojun , et al . Neferine hinders choriocarcinoma cell proliferation,migration and invasion through repression of long noncoding RNA-CHRF [J]. Artif Cells Nanomed Biotechnol , 2019 , 47 ( 1 ): 4089 - 4096 .
ZHOU J , LI G , ZHENG Y , et al . A novel autophagy/mitophagy inhibitor liensinine sensitizes breast cancer cells to chemotherapy through DNM1L-mediated mitochondrial fission [J]. Autophagy , 2015 , 11 ( 8 ): 1259 - 1279 .
SHU G , ZHANG L , JIANG S , et al . Isoliensinine induces dephosphorylation of NF- k B p65 subunit at Ser536 via a PP2A-dependent mechanism in hepatocellular carcinoma cells:roles of impairing PP2A/I2PP2A interaction [J]. Oncotarget , 2016 , 7 ( 26 ): 40285 - 40296 .
LIU X , WANG P , ZHANG C , et al . Epidermal growth factor receptor (EGFR): a rising star in the era of precision medicine of lung cancer [J]. Oncotarget , 2017 , 8 ( 30 ): 50209 - 50220 .
TAN , A C . Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC) [J]. Thorac Cancer , 2020 , 11 ( 3 ): 511 - 518 .
TADESSE S , ANSHABO A T , PORTMAN N , et al . Targeting CDK2 in cancer: challenges and opportunities for therapy [J]. Drug Discov Today , 2020 , 25 ( 2 ): 406 - 413 .
ZHANG Z Y , GAO X H , MA M Y , et al . CircRNA 101237 promotes NSCLC progression via the miRNA 490-3p/MAPK1 axis [J]. Sci Rep , 2020 , 10 ( 1 ): 9024 .